{"nctId":"NCT03066830","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","startDateStruct":{"date":"2017-02-24","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":507,"armGroups":[{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sotagliflozin (SAR439954)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Metformin","Drug: Sulfonylurea"]}],"interventions":[{"name":"Sotagliflozin (SAR439954)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Sulfonylurea","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\n* Participants with T2D treated with a Sulfonylurea (≥half the maximum recommended dose as per local label or maximum tolerated dose \\[documented\\]) as monotherapy or in combination with Metformin (≥1500 mg per day or maximum tolerated dose \\[documented\\]) each at a stable dose for at least 12 weeks without a dose adjustment before screening.\n* Signed written informed consent.\n\nExclusion criteria:\n\n* At the time of screening, age \\<18 years or \\< legal age of majority, whichever is greater.\n* Body Mass Index (BMI) ≤20 or \\>45 kilograms per meter square (kg/m\\^2) at Screening.\n* Hemoglobin A1c (HbA1c) \\<7% or HbA1c \\>10% via central lab test at screening.\n* Fasting plasma glucose (FPG) \\>15 mmol/L (270 mg/dL) measured by the central laboratory at screening (Visit 1), and confirmed (\\>15 mmol/L \\[270 mg/dL\\]) by a repeat test before randomization.\n* Women of childbearing potential with no effective contraceptive method.\n* Treated with an antidiabetic pharmacological regimen other than a Sulfonylurea at a stable dose with or without Metformin within 12 weeks preceding the screening visit.\n* Previous insulin use \\>1 month (at any time, aside from treatment of gestational diabetes).\n* History of prior gastric surgical procedure including gastric banding or inflammatory bowel disease within 3 years before the Screening Visit.\n* History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.\n* History of severe hypoglycemia within 6 months prior to the Screening visit.\n* Systolic blood pressure (SBP) \\>180 millimeter per mercury (mmHg) or diastolic blood pressure (DBP) \\>100 mmHg or history of hypertensive emergency.\n* Aspartate aminotransferase and/or alanine aminotransferase: \\>3 times the upper limit of the normal laboratory range (ULN).\n* Total bilirubin: \\>1.5 times ULN (except in case of Gilbert's syndrome).\n* Use of systemic glucocorticoids (excluding topical or ophthalmic, application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.\n* Pregnancy, breastfeeding.\n* Participants is unwilling to perform self-monitoring of blood glucose (SMBG), and complete the participant's diary as required per protocol.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26","description":"Missing data are imputed using the retrieved dropouts imputation method. An analysis of covariance (ANCOVA) model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.082"},{"groupId":"OG001","value":"-0.70","spread":"0.068"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26","description":"Missing data are imputed using the retrieved dropouts imputation method. An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.277","spread":"0.2691"},{"groupId":"OG001","value":"-1.331","spread":"0.1844"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg","description":"Missing data are imputed using the washout imputation method under the missing, not at random framework. An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.58","spread":"1.052"},{"groupId":"OG001","value":"-4.41","spread":"1.061"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SBP at Week 12 for All Participants","description":"Missing data are imputed using washout imputation method under the missing not at random framework. An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"0.826"},{"groupId":"OG001","value":"-1.71","spread":"0.830"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 26","description":"Missing data are imputed using the retrieved dropouts imputation method. An ANCOVA model was used for the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"0.206"},{"groupId":"OG001","value":"-1.70","spread":"0.215"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <6.5% at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.0% at Week 26","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"26.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Hypoglycemic Events","description":"Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \\[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\\]; Severe \\[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\\] or documented symptomatic hypoglycemia \\[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\\]. Participants may be reported in more than one category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":253},"commonTop":["Hyperglycaemia","Nasopharyngitis","Diarrhoea","Upper respiratory tract infection","Urinary tract infection"]}}}